GUZI, Timothy, Kamil PARUCH, Michael DWYER, David PARRY, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY, Arshad SIDDIQUI and Praveen TADIKONDA. Methods for inhibiting protein kinases. Online. 2007, [citováno 2024-04-23]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Methods for inhibiting protein kinases
Name in Czech Methods for inhibiting protein kinases
Authors GUZI, Timothy, Kamil PARUCH, Michael DWYER, David PARRY, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY, Arshad SIDDIQUI and Praveen TADIKONDA
Edition Number: US 2007/0105864 A1, Publisher: United States Patent and Trademark Office, Place of publication: USA, Owner's name: Schering-Plough, 2007.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
Keywords (in Czech) kinases; cancer; inhibitor
Keywords in English kinases; cancer; inhibitor
Tags cancer, inhibitor, kinases
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 15:02.
Abstract
The invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compds. of formula I and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with protein kinases using such compds. Compds. of formula I wherein R is H, halo, (un)substituted (hetero)aryl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocyclyl, etc.; R1 is H, halo, and alkyl; R2 is alkyl, (un)substituted (hetero)aryl(alkyl), alkenyl, alkynyl, etc.; R3 is H, (un)substituted (hetero)aryl(alkyl), (un)substituted heterocyclyl(alkyl), (un)substituted (hetero)cycloalkyl, etc.; and their pharmaceutically acceptable salts, solvates, esters, and prodrugs thereof are claimed. Example compd. II was prepd. by amination of 3-(1-methylpyrazol-4-yl)-7-methylsulfonylimidazo[1,2-a]pyrazine with 3-(methylsulfonyl)aniline. All the invention compds. were evaluated for their protein kinase inhibitory activity (data given).
Abstract (in Czech)
viz Anotace
PrintDisplayed: 23/4/2024 17:21